Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 2

Conditions

Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Myelodysplastic Syndromes 4Neoplasms, Plasma Cell 3Melanoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Primary Myelofibrosis 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Lymphoma, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Glioblastoma 2Burkitt Lymphoma 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Philadelphia Chromosome 1Pancreatic Neoplasms 1Osteosarcoma 1

Interventions

Imatinib Mesylate 142nilotinib 94Cyclophosphamide 91fludarabine phosphate 75fludarabine 67Dasatinib 63Mycophenolic Acid 60Whole-Body Irradiation 59Tacrolimus 47Busulfan 45Cyclosporine 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 35Melphalan 30bosutinib 27ponatinib 26Granulocyte Colony-Stimulating Factor 26thymoglobulin 25Thiotepa 25Methotrexate 25Filgrastim 25asciminib 24Antilymphocyte Serum 24Stem Cell Transplantation 22Sirolimus 17Interferon-alpha 16sargramostim 15Cord Blood Stem Cell Transplantation 14Clofarabine 13Bone Marrow Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Blood Component Removal × Clear all
NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
24 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06059391 2026-03-10

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center

Phase 2 Recruiting
216 enrolled
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00499889 2012-04-23

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

M.D. Anderson Cancer Center

Phase 2 Terminated
42 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡